Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Agreement #CSEStocks #OTC #OTCMarkets #OTCStocks #SmallCaps #Investing
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to give an update on its Orano Support SAS partnership in the radiopharmaceuticals field, on behalf of Orano SAS ("Orano"), a world-renowned multinational nuclear company, headquartered in France.Defence is developing in...
http://dlvr.it/TBrc1t
http://dlvr.it/TBrc1t
Comments
Post a Comment